Biodrugs

Papers
(The TQCC of Biodrugs is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Designer Exosomes: A New Platform for Biotechnology Therapeutics128
Therapeutic siRNA: State-of-the-Art and Future Perspectives87
Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future61
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease58
Beyond Antibodies: The DARPin® Drug Platform54
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy48
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks44
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins44
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic41
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges36
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption36
The Importance of Countering Biosimilar Disparagement and Misinformation34
Dengue Vaccines: An Update33
Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study33
The Path Towards a Tailored Clinical Biosimilar Development32
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice32
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma31
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis29
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success29
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond29
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA27
Teserpaturev/G47Δ: First Approval25
Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study25
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration25
The Immunotherapy Landscape in Renal Cell Carcinoma24
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin24
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering24
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology23
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants23
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis23
Targeted Therapies for Eosinophilic Gastrointestinal Disorders22
Monoclonal Antibody-Based Therapies for Myasthenia Gravis21
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities21
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer21
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial20
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets20
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale19
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy19
Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update19
New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database18
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management18
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis18
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?18
Plant-Derived Human Vaccines: Recent Developments18
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies18
Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy17
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe16
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project16
Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development15
Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence15
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey15
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer15
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience15
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?14
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)14
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine13
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 13
Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review13
Targeting IL-36 in Inflammatory Skin Diseases13
0.034929037094116